CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease

CRISPR-mediated gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease resulted in functional human leukocytes in mice after transplantation. Seamless gene repair with CRISPR Targeted gene therapy has been hampered by the inability to correct mutations in stem cells that can reconstitute the immune system after transplant into patients. De Ravin et al. now report that CRISPR, a DNA editing technology, corrected blood stem cells from patients with an immunodeficiency disorder (chronic granulomatous disease) caused by mutations in NOX2. CRISPR-repaired human stem cells engrafted in mice after transplant and differentiated into leukocytes with a functional NOX2 protein for up to 5 months. The authors did not detect off-target treatment effects, suggesting that this gene repair strategy may benefit patients with chronic granulomatous disease or other blood disorders. Gene repair of CD34+ hematopoietic stem and progenitor cells (HSPCs) may avoid problems associated with gene therapy, such as vector-related mutagenesis and dysregulated transgene expression. We used CRISPR (clustered regularly interspaced short palindromic repeat)/Cas9 (CRISPR-associated 9) to repair a mutation in the CYBB gene of CD34+ HSPCs from patients with the immunodeficiency disorder X-linked chronic granulomatous disease (X-CGD). Sequence-confirmed repair of >20% of HSPCs from X-CGD patients restored the function of NADPH (nicotinamide adenine dinucleotide phosphate) oxidase and superoxide radical production in myeloid cells differentiated from these progenitor cells in vitro. Transplant of gene-repaired X-CGD HSPCs into NOD (nonobese diabetic) SCID (severe combined immunodeficient) γc−/− mice resulted in efficient engraftment and production of functional mature human myeloid and lymphoid cells for up to 5 months. Whole-exome sequencing detected no indels outside of the CYBB gene after gene correction. CRISPR-mediated gene editing of HSPCs may be applicable to other CGD mutations and other monogenic disorders of the hematopoietic system.

[1]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[2]  S. Holland,et al.  Residual NADPH oxidase and survival in chronic granulomatous disease. , 2010, The New England journal of medicine.

[3]  A. Thrasher,et al.  Patching up hematopoietic stem cells , 2015, Nature Biotechnology.

[4]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[5]  M. van der Burg,et al.  Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.

[6]  P. Disterer,et al.  Use of internally nuclease‐protected single‐strand DNA oligonucleotides and silencing of the mismatch repair protein, MSH2, enhances the replication of corrected cells following gene editing , 2009, The journal of gene medicine.

[7]  H. Malech,et al.  Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiency , 2015, Transfusion.

[8]  Kathryn L. Parsley,et al.  Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  D. Trono,et al.  Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  J. Doudna,et al.  The use of CRISPR/Cas9, ZFNs, TALENs in generating site specific genome alterations , 2014 .

[11]  R. Sitia,et al.  AQP8 transports NOX2‐generated H2O2 across the plasma membrane to promote signaling in B cells , 2016, Journal of leukocyte biology.

[12]  L. Notarangelo,et al.  Immune deficiencies, infection, and systemic immune disordersComparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency , 2014 .

[13]  Lei Zhang,et al.  Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. , 2015, Blood.

[14]  J. Doudna,et al.  Methods in Enzymology. The use of CRISPR/Cas9, ZFNs, and TALENs in generating site-specific genome alterations. Preface. , 2014, Methods in enzymology.

[15]  H. Nakauchi,et al.  An assessment of the effects of ectopic gp91phox expression in XCGD iPSC-derived neutrophils , 2015, Molecular therapy. Methods & clinical development.

[16]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[17]  Shondra M. Pruett-Miller,et al.  Gene editing using ssODNs with engineered endonucleases. , 2015, Methods in molecular biology.

[18]  T. Chun,et al.  Humans with chronic granulomatous disease maintain humoral immunologic memory despite low frequencies of circulating memory B cells. , 2012, Blood.

[19]  J. Joung,et al.  Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition , 2015, Nature Biotechnology.

[20]  Luca Biasco,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome , 2013, Science.

[21]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[22]  J. Joung,et al.  High-fidelity CRISPR-Cas9 variants with undetectable genome-wide off-targets , 2015, Nature.

[23]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[24]  P. Renz,et al.  CRISPR-mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells , 2015, Experimental hematology.

[25]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[26]  Adrian W. Briggs,et al.  Stable Gene Targeting in Human Cells Using Single-Strand Oligonucleotides with Modified Bases , 2012, PloS one.

[27]  B. Smart.  Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome , 2011, Pediatrics.

[28]  Yanpeng Wang,et al.  Genome editing in rice and wheat using the CRISPR/Cas system , 2014, Nature Protocols.

[29]  C. Cale,et al.  Clinical Manifestations of Disease in X-Linked Carriers of Chronic Granulomatous Disease , 2013, Journal of Clinical Immunology.

[30]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[31]  Adeline R. Whitney,et al.  Innate Immunity against Granulibacter bethesdensis, an Emerging Gram-Negative Bacterial Pathogen , 2011, Infection and Immunity.

[32]  Martin J. Aryee,et al.  Engineered CRISPR-Cas9 nucleases with altered PAM specificities , 2015, Nature.

[33]  L. Notarangelo,et al.  Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency , 2016, Science Translational Medicine.